诱导化疗联合调强放疗治疗食管鳞状细胞癌的治疗模式及预后分析

W. Du, X. Gu, Xian-shu Gao, Jie Li, Xueqin Wu
{"title":"诱导化疗联合调强放疗治疗食管鳞状细胞癌的治疗模式及预后分析","authors":"W. Du, X. Gu, Xian-shu Gao, Jie Li, Xueqin Wu","doi":"10.3760/CMA.J.ISSN.0254-5098.2019.12.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze the therapeutic effect and prognostic factors of induction chemotherapy plus intensity-modulated radiotherapy (IMRT) with or without consolidation chemotherapy for esophageal squamous cell carcinoma (ESCC). \n \n \nMethods \nOne hundred and eight patients with ESCC treated between January 2010 to August 2014 were analyzed retrospectively. All patients received IMRT and platinum-based chemotherapy. The overall survival (OS) and local control (LC) rates were calculated using the Kaplan-Meier method and the univariate prognostic analyses were tested by the Log-rank test. The Cox proportional hazard model was used for multivariate prognostic analysis. \n \n \nResults \nThe follow-up rate was 97.2%. The 1-, 3- and 5-year survival rates were 76.9%, 50.9% and 32.3% respectively, and the LC rates were 73.6%, 58.5% and 54.9% respectively. The median OS with and without consolidation chemotherapy were 51 and 15 months (χ2=5.076, P=0.024), respectively. Multivariate analysis showed that clinical N staging, recent curative effect and consolidation chemotherapy were important prognostic factors for OS, and recent curative effect was associated with LC. The rates of acute grade 3 radiation-induced esophagitis, gastrointestinal side effects, myelosuppression and radiation-induced pulmonary injury were 7.4%, 6.5%, 12% and 0.9%, respectively, and no grade 4 occurred. The late toxicity was mainly radiation-induced pulmonary fibrosis. \n \n \nConclusions \nInduction chemotherapy plus IMRT with or without consolidation chemotherapy is safe and effective in the treatment of ESCC. The addition of consolidation chemotherapy may help prolong the survival of some patients and further research is necessary. Individualized treatment should be selected for patients who cannot tolerate or refuse concurrent chemoradiotherapy. \n \n \nKey words: \nEsophageal neoplasms; IMRT; Induction chemotherapy; Sequential; Prognosis","PeriodicalId":36403,"journal":{"name":"中华放射医学与防护杂志","volume":"1 1","pages":"920-925"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discussion on the treatment model and prognostic analysis of esophageal squamous cell carcinoma treated with induction chemotherapy combined with intensity-modulated radiation therapy\",\"authors\":\"W. Du, X. Gu, Xian-shu Gao, Jie Li, Xueqin Wu\",\"doi\":\"10.3760/CMA.J.ISSN.0254-5098.2019.12.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo analyze the therapeutic effect and prognostic factors of induction chemotherapy plus intensity-modulated radiotherapy (IMRT) with or without consolidation chemotherapy for esophageal squamous cell carcinoma (ESCC). \\n \\n \\nMethods \\nOne hundred and eight patients with ESCC treated between January 2010 to August 2014 were analyzed retrospectively. All patients received IMRT and platinum-based chemotherapy. The overall survival (OS) and local control (LC) rates were calculated using the Kaplan-Meier method and the univariate prognostic analyses were tested by the Log-rank test. The Cox proportional hazard model was used for multivariate prognostic analysis. \\n \\n \\nResults \\nThe follow-up rate was 97.2%. The 1-, 3- and 5-year survival rates were 76.9%, 50.9% and 32.3% respectively, and the LC rates were 73.6%, 58.5% and 54.9% respectively. The median OS with and without consolidation chemotherapy were 51 and 15 months (χ2=5.076, P=0.024), respectively. Multivariate analysis showed that clinical N staging, recent curative effect and consolidation chemotherapy were important prognostic factors for OS, and recent curative effect was associated with LC. The rates of acute grade 3 radiation-induced esophagitis, gastrointestinal side effects, myelosuppression and radiation-induced pulmonary injury were 7.4%, 6.5%, 12% and 0.9%, respectively, and no grade 4 occurred. The late toxicity was mainly radiation-induced pulmonary fibrosis. \\n \\n \\nConclusions \\nInduction chemotherapy plus IMRT with or without consolidation chemotherapy is safe and effective in the treatment of ESCC. The addition of consolidation chemotherapy may help prolong the survival of some patients and further research is necessary. Individualized treatment should be selected for patients who cannot tolerate or refuse concurrent chemoradiotherapy. \\n \\n \\nKey words: \\nEsophageal neoplasms; IMRT; Induction chemotherapy; Sequential; Prognosis\",\"PeriodicalId\":36403,\"journal\":{\"name\":\"中华放射医学与防护杂志\",\"volume\":\"1 1\",\"pages\":\"920-925\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华放射医学与防护杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.0254-5098.2019.12.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射医学与防护杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-5098.2019.12.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的分析诱导化疗加调强放疗伴或不伴巩固化疗治疗食管鳞状细胞癌的疗效及影响预后的因素。方法对2010年1月~ 2014年8月收治的118例ESCC患者进行回顾性分析。所有患者均接受IMRT和铂类化疗。总生存期(OS)和局部控制率(LC)采用Kaplan-Meier法计算,单因素预后分析采用Log-rank检验。采用Cox比例风险模型进行多因素预后分析。结果随访率为97.2%。1、3、5年生存率分别为76.9%、50.9%和32.3%,LC率分别为73.6%、58.5%和54.9%。合并化疗和未合并化疗的中位OS分别为51个月和15个月(χ2=5.076, P=0.024)。多因素分析显示,临床N分期、近期疗效及巩固化疗是影响OS预后的重要因素,近期疗效与LC相关。急性3级放射性食管炎、胃肠道副反应、骨髓抑制和放射性肺损伤发生率分别为7.4%、6.5%、12%和0.9%,未发生4级。晚期毒性主要为辐射引起的肺纤维化。结论诱导化疗加IMRT伴或不伴巩固化疗是治疗ESCC安全有效的方法。合并巩固化疗可能有助于延长部分患者的生存期,需要进一步的研究。对于不能耐受或拒绝同步放化疗的患者,应选择个体化治疗。关键词:食管肿瘤;强度;诱导化疗;顺序;预后
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Discussion on the treatment model and prognostic analysis of esophageal squamous cell carcinoma treated with induction chemotherapy combined with intensity-modulated radiation therapy
Objective To analyze the therapeutic effect and prognostic factors of induction chemotherapy plus intensity-modulated radiotherapy (IMRT) with or without consolidation chemotherapy for esophageal squamous cell carcinoma (ESCC). Methods One hundred and eight patients with ESCC treated between January 2010 to August 2014 were analyzed retrospectively. All patients received IMRT and platinum-based chemotherapy. The overall survival (OS) and local control (LC) rates were calculated using the Kaplan-Meier method and the univariate prognostic analyses were tested by the Log-rank test. The Cox proportional hazard model was used for multivariate prognostic analysis. Results The follow-up rate was 97.2%. The 1-, 3- and 5-year survival rates were 76.9%, 50.9% and 32.3% respectively, and the LC rates were 73.6%, 58.5% and 54.9% respectively. The median OS with and without consolidation chemotherapy were 51 and 15 months (χ2=5.076, P=0.024), respectively. Multivariate analysis showed that clinical N staging, recent curative effect and consolidation chemotherapy were important prognostic factors for OS, and recent curative effect was associated with LC. The rates of acute grade 3 radiation-induced esophagitis, gastrointestinal side effects, myelosuppression and radiation-induced pulmonary injury were 7.4%, 6.5%, 12% and 0.9%, respectively, and no grade 4 occurred. The late toxicity was mainly radiation-induced pulmonary fibrosis. Conclusions Induction chemotherapy plus IMRT with or without consolidation chemotherapy is safe and effective in the treatment of ESCC. The addition of consolidation chemotherapy may help prolong the survival of some patients and further research is necessary. Individualized treatment should be selected for patients who cannot tolerate or refuse concurrent chemoradiotherapy. Key words: Esophageal neoplasms; IMRT; Induction chemotherapy; Sequential; Prognosis
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中华放射医学与防护杂志
中华放射医学与防护杂志 Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
0.60
自引率
0.00%
发文量
6377
期刊介绍:
期刊最新文献
Infection control status of novel coronavirus pneumonia and radiation safety at CT workplace Current status of the application of radiodiagnosis and radiotherapy resources in Huai'an City in 2020 The application value of low-dose CT scan in pregnant women with COVID-19 Eeffects of tube voltage on image quality and radiation dose of paranasal sinus CT examination Analyzing quality of life and influencing factors in patients with bone metastasis of hepatocellular carcinoma before and after radiotherapy by bone pain scale
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1